NCT00794950 2019-09-23
Sutent
University of Michigan
Phase 2 Completed
Clinical Trials
11 trialsNCT01118351 2019-05-01
Sunitinib Malate in Treating Patients With Recurrent Transitional Cell Bladder Cancer
Case Comprehensive Cancer Center
Phase 2 Terminated
NCT00526656 2019-04-16
Sunitinib in Treating Patients With Locally Advanced Bladder Cancer
Case Comprehensive Cancer Center
Phase 2 Completed
NCT01089088 2018-10-26
Gemcitabine Hydrochloride, Cisplatin, and Sunitinib Malate as First-Line Therapy in Treating Patients With Locally Advanced And/or Metastatic Transitional Cell Carcinoma of the Urothelium (SUCCINCT)
Cardiff University
Phase 2 Completed
NCT01042795 2017-06-28
Trial of Adjuvant Sutent for Patients With High Risk Urothelial Carcinoma After Neoadjuvant Chemotherapy and Cystectomy
University of Michigan
Phase 2 Terminated
NCT00847015 2016-02-29
Gemcitabine, Cisplatin, and Sunitinib (GC-S) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00397488 2016-01-25
Sunitinib in Treating Patients With Progressive Metastatic Transitional Cell Cancer of the Urothelium
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00393796 2014-11-13
Trial of Maintenance SUO11248 Versus Placebo Post Chemotherapy for Patients With Advanced Urothelial Carcinoma
University of Michigan Rogel Cancer Center
Phase 2 Terminated
NCT01118039 2013-08-07
Sunitinib Malate in Treating Patients With Locally Recurrent, Locally Advanced, Unresectable, or Metastatic Urinary Tract Cancer
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00792025 2011-05-17
Sunitinib as Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Transitional Cell Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00818350 2009-01-07
Activity Study of Sunitinib In Metastatic Pretreated Urothelial Cancer
Campania Younger Oncologists Association
Phase 1/2 Unknown